Objectives: From around year 2000, impetigo caused by fusidic acid-resistant Staphylococcus aureus was observed in countries of Northern Europe. The bacteria were found to represent a clone, the epidemic European fusidic acid-resistant impetigo clone (EEFIC). This study reports longitudinal data on the incidence and bacteriology of impetigo in a Norwegian island community during the years 2001-09.
Introduction
Impetigo is a superficial skin infection most commonly found in children. 1 Staphylococcus aureus and group A streptococci are the bacterial agents commonly related to impetigo, the former being in the majority. Superficial staphylococcal skin infections are among the indications for use of the antibiotic fusidic acid. Its antibacterial action is inhibition of bacterial protein synthesis by interfering with dissociation of elongation factor G (EF-G) from the ribosome. Resistance to fusidic acid in S. aureus is caused by a genetic mutation causing alteration of the EF-G protein (FusA class) or by expression of a protein that protects the drug target on the EF-G (FusB and FusC classes). 2 The corresponding gene determinants are designated fusA, which is considered to originate from spontaneous mutations in the chromosomally located gene for EF-G, and fusB and fusC, which may both be chromosomal-or plasmid-mediated, and are considered acquired resistance genes.
In 2002 one Norwegian and one Swedish study were published reporting laboratory data from 2000 and 2001 on the increasing incidence of impetigo-associated fusidic acid-resistant S. aureus, and genetic analysis by PFGE showed that the great majority of isolates from both countries belonged to a single clone. 3, 4 In 2004 one study from the UK, reporting data from 1997-2001, demonstrated a high frequency of S. aureus resistance to fusidic acid in impetigo, and consecutive molecular analyses of isolates from 2002 showed that the fusidic acid-resistant isolates belonged to one clone. 5 The EPISA study of antimicrobial susceptibility of S. aureus-related skin and soft tissue infections in France, the UK and Ireland during 2003 -04 also studied the prevalence of the epidemic European fusidic acid-resistant impetigo clone (EEFIC) in general practice. The proportion of EEFIC was 78% for impetigo in UK and Ireland. 6 During what was perceived as an epidemic outbreak of impetigo in 2003, 15 impetigo isolates from Norway, Sweden, Denmark, Ireland and the UK were analysed by O'Neill et al. They found these strains to represent a clone that carried a chromosomal fusB determinant. Resistance to fusidic acid in a collection of non-impetigo strains resulted, on the other hand, primarily from mutations in fusA. The clone was designated EEFIC. O'Neill et al. later performed detailed characterization of the clone. Molecular typing revealed the EEFIC to belong to the genetic type ST123, spa type t171 and agr type IV. PCR analysis identified genes encoding toxins implicated in impetigo (exfoliative toxins A and B and EDIN-C).
From Norway, we reported data from a longitudinal study of impetigo in the entire population of the island community of Austevoll, Western Norway, during the years 2001 -05, 1 where we documented outbreaks of impetigo in the seasons of summer and early autumn in the period 2002-04, which were related to fusidic acid-resistant S. aureus. We here present continued data on impetigo from the same population, over a time span of 8.5 years. The aims of the present study were as follows: first, to report the incidence of impetigo over a long time period; second, to report changes in fusidic acid resistance in impetigo-related S. aureus over time; and third, to investigate if the EEFIC is still responsible for most impetigo cases in this population.
Methods
The study was conducted as a long-term population-based investigation. The population of the community was 4417 by 1 January 2009, and this number was used to calculate incidence rates. Ferries and boats are the only connection with the mainland. There are four general practitioners in the municipality. They identified all patients with the clinical diagnosis of impetigo and were urged to collect a swab for bacteriological analysis of all cases.
The methods of identifying the patients and their inclusion in the study have been described in detail previously. 1 In short, we made an operational definition of impetigo as being a superficial skin infection with spontaneous erosions and/or crusts and/or bullae. The basis for inclusion of impetigo cases was patients seen by the doctor and diagnosed as having impetigo. Incidence rates are given per person-year.
Throughout the study period, all the bacteriological specimens were investigated at the Department of Medical Microbiology, Haukeland University Hospital, Norway. Fusidic acid susceptibility was determined by disc diffusion according to the routine procedures of the laboratory.
MICs of erythromycin, clindamycin, fusidic acid, ciprofloxacin, tetracycline, co-trimoxazole and rifampicin were determined using Etest (AB Biodisk, Solna, Sweden) on Mueller-Hinton II agar medium according to the manufacturer's instructions. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint was used to categorize the isolates as susceptible (MIC ≤1 mg/L) or resistant (MIC. 1 mg/L) to fusidic acid. PFGE using SmaI was carried out as described in the Nordic PFGE protocol. 8 Comparisons were made with a reference strain which belongs to the EEFIC and is identical to a strain investigated by Tveten et al. 3 and O'Neill et al. 7 Band patterns were compared visually and differences evaluated as described by Tenover et al. 9 According to the degree of relatedness to the reference strain, the isolates were assigned as being identical, closely related, possibly related or not related.
Isolates indicated by PFGE to belong to the EEFIC were further analysed by staphylococcal protein A (spa) typing. This was done in St Olav's University Hospital, Department of Medical Microbiology, Trondheim, Norway, and was performed as previously described. 10 The spa types were assigned through the Ridom database. spa types that shared identical repeat units arranged in an identical or similar order were assigned as identical or closely related, respectively. spa types with repeat units that differed markedly from the reference strain were assigned as not related. Additionally, isolates showing resistance to fusidic acid by Etest were spa typed. To be defined as EEFIC in the present study, isolates had to show both PFGE pattern and spa typing to be at least closely related to the EEFIC reference strain.
For comparison of the impetigo-causing strains of S. aureus with strains causing other types of superficial skin infections, one of the general practitioners (S. R.) collected swabs from such infections as well. For those specimens yielding growth of S. aureus, a disc diffusion test, Etest and PFGE analysis were performed as described above.
Data were registered and analysed in SPSS 18.0. We performed x 2 analyses for comparison of proportions and for tests for trend. P values ,0.05 were considered significant. 
Results and discussion
The annual incidences of impetigo for the period 2001-09 are given in Table 1 . After a maximum in 2002, there was Rørtveit et al.
a marked decline in incidence (P,0.001). Bacterial swabs were taken from 79% of the patients, and S. aureus was grown in 77% of the cases where swabs were taken ( Table 1) From the 52 impetigo cases in 2008 and 2009, 50 swabs were taken and S. aureus isolated in 33. Of these, 28 were investigated by Etest and PFGE analysis and 13 were consecutively spa typed. Of the 28 S. aureus isolates that were subject to molecular analyses, 11 were found to be related to the EEFIC (Table 2 ). None showed PFGE identity with the reference strain collected in 2001, but eight had an identical spa type (t171), while three isolates had closely related spa types. One of these was susceptible to fusidic acid. The others were resistant to fusidic acid, with MIC values of 3-4 mg/L. The EEFIC clone was responsible for 83% (10 out of 12) of S. aureus isolates with resistance to fusidic acid, and 91% (10 out of 11) of EEFIC isolates were resistant to fusidic acid.
From 11 S. aureus isolates from skin infections other than impetigo analysed by Etest and PFGE, all turned out to be fusidic acid susceptible, and none was related to the EEFIC. The results of Etest analysis are shown in Table 2 .
Generally, previous studies of the prevalence of EEFIC-related impetigo have reported data from hospitals or general practice without access to the denominator of the population they are recruiting from, and hence cannot provide incidence statistics. Thus, the notion that there has been an epidemic of impetigo in Scandinavia, the UK and Ireland caused by the EEFIC has scarcely been supported by evidence until now. Our data are based on the total number of impetigo cases registered in general practice in a well-defined community, which allows precise estimates of incidence. In this community there were outbreaks of impetigo related to fusidic acid-resistant S. aureus during the years 2002-04, and marked declines in the incidence of impetigo and also of fusidic acid resistance in impetigo-related S. aureus have occurred in the years after that. Our data show that for the years 2008 -09 the EEFIC was still responsible for the majority of cases of fusidic acid-resistant impetigo in our community.
An important question is what has happened to fusidic acid resistance in S. aureus related to superficial skin infections and to the EEFIC. Recently, a Swedish study in patients attending a dermatological outpatient clinic for impetigo and infected atopic dermatitis in the years 2004 -08 showed that in 2004, 33% and 12% of the S. aureus isolates were resistant to fusidic acid in impetigo and infected atopic dermatitis, respectively. In 2008 the corresponding figures were 24% and 2.2%, indicating a diminishing rate of S. aureus resistance to fusidic acid in superficial skin infections. 11 No molecular typing was performed. The Norwegian Surveillance System for Antimicrobial Resistance reported that the proportion of S. aureus from skin and soft tissue infections being resistant to fusidic acid was steadily falling from a maximum of 25% in 2004 to about 10% in 2008, interpreting this as probably stemming from reduced presence of the EEFIC. 12 The strength of the present study is the consistent and maintained ascertainment of impetigo diagnoses in the total population of a geographically demarcated community over a long time span, thus being able to present incidence and proportions with a high reliability. The main weakness is that we have molecular data only for the last 2 years.
